To include your compound in the COVID-19 Resource Center, submit it here.

Novo jumps after outperforming Street and raising guidance

Pharma giant Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) bucked expectations and raised its fiscal 2017 guidance after reporting 2Q17 earnings figures that outperformed the Street's expectations.

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE